Eli Lilly & Co.’s blockbuster obesity shot Zepbound helped people with type 1 diabetes lose more than a fifth of their body ...

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...

A recent announcement by Eli Lilly suggests that the company understands the economic conundrum some patients face. Per a ...

Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...

The weight management drug Zepbound will now be sold in lower-cost vials in addition to preloaded injector pens, according to ...

More research is needed to understand why the drug works better for women Get any of our free email newsletters — news ...

Although women lost more weight, all participants saw significant decreases in total body weight on all doses of the medication.

People who are in need of weight loss medications but do not have insurance coverage will soon have a new way to access one ...

Results from 4 studies revealed that women lost more weight on average than men when taking tirzepatide — but they also ...

Eli Lilly's weight loss treatment Zepbound might be a blockbuster in the making, but it wasn't without its challenges. See ...

Millions turn to compounded versions of popular weight loss drugs amid shortages and high costs.